DMA4-H228
DC60856
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | CICL-1 (L829) |
| Synonyms | L-829, L 829, Capstan-lipid-CICL-1, Capstanlipid CICL1, CICL1, CICL 1, CICL-1, Lipid 829, L-829, L 829, Compound A-11, DC60860 |
| SMILES | CCCCCCCCC(=O)OCC(COC(=O)CCCCCCCC)CC(=O)OCCN(CCOC(=O)CC(COC(=O)CCCCCCCC)COC(=O)CCCCCCCC)C(=O)OCCN(C)C |
| Formula | C55H100O14N2 |
| M.Wt | 1,013.40 |
| Purity | >98% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Hunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311-1317. |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| L829 (CICL-1) | Not reported | Ionizable lipid |
| Anti-CD8 targeting-moiety lipid conjugate (lipid identity not reported in supplied main article) | Not reported | Targeting-lipid conjugate |
| Three additional lipid components (identities not reported in supplied main article) | Not reported | Additional lipid components |
| Reported total | Not reported | Source values retained |
Formulation calculator unavailable. The supplied article does not report the complete molar composition, so a formulation weight calculation is not available. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reportedSharp decline by 6 h; near-undetectable by 24 h6 and 24 h after first IV dose · After the first CD8-L829-tLNP-CD20 doseFigure 4B and main text, Science p. 1316
Literature-reportedUp to 85%After the third IV dose · Minimal CAR expression on CD4+ T cellsFigure 4C and main text, Science p. 1316
Literature-reportedUp to 95%After the third IV dose · Dose-dependent expression was reportedFigure 4C and main text, Science p. 1316
Literature-reportedRepopulation began around day 21 and approached baseline by day 35Recovery follow-up after 1-1.5 mg/kg dosing · Repopulating blood and tissue B cells were predominantly naïveFigure 5, Figure S12 and main text, Science p. 1316
Additional reported findings
At 30 µg, four of five mice showed near-complete tumor clearance two days after the first dose, and all five did so three days after the second dose.
CD8-L829-tLNP-CD19; IV 30 µg; twice weekly for five doses; human PBMC plus Nalm6 xenograft · Figure 3G and main text, Science p. 1315The study reported lower liver and spleen luciferase expression with untargeted L829 LNP than with the ALC-0315 benchmark, and rapid L829 clearance from mouse liver while ALC-0315 remained elevated for at least seven days.
Luciferase mRNA and LC-MS studies; WT C57BL/6 mice · Figure 1B,C and main text, Science pp. 1311-1312Rat CD5-L829 tLNP was reported as tolerated up to 5 mg/kg without adverse observations, and a single 3 mg/kg IV dose was reported as safely administered in cynomolgus monkeys. In the repeat-dose anti-CD20 study, however, one monkey in the 1.5 mg/kg group developed a serious immune-effector-cell-associated event 72 h after the third dose and was euthanized.
Study-specific targeted L829 tLNPs; rat and cynomolgus-monkey experiments · Figure 1D,E; main text, Science pp. 1311 and 1316Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetHunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311-1317. DOI: 10.1126/science.ads8473
Identity and performance: supplied Science main article, Figures 1 and 3-5. The complete five-lipid composition, preparation method and particle-characterization details are assigned by the article to Supplementary Table S1 and Materials and Methods, which were not present in the uploaded PDF.
Identity and performance: supplied Science main article, Figures 1 and 3-5. The complete five-lipid composition, preparation method and particle-characterization details are assigned by the article to Supplementary Table S1 and Materials and Methods, which were not present in the uploaded PDF.